Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs

Clinical and Experimental Rheumatology

Volumn 36, Issue 2, 2018, Pages 317-328

  Meroni, Pier Luigi ^a   Zavaglia, Daniela ^b   Girmenia, Corrado ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b PFIZER INC   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Infections; Rheumatoid arthritis; Vaccinations

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HEPATITIS B VACCINE; IMMUNOMODULATING AGENT; INFLIXIMAB; INFLUENZA VACCINE; NEW DRUG; PNEUMOCOCCUS VACCINE; RITUXIMAB; TOCILIZUMAB; TOFACITINIB; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; ANTIRHEUMATIC AGENT;

ADULT; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EUROPE; HEPATITIS B; HERPES ZOSTER; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFLUENZA; INFLUENZA VACCINATION; INTERNATIONAL COOPERATION; MEDICAL PRACTICE; MORBIDITY; MORTALITY; PAPILLOMAVIRUS INFECTION; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGIST; VACCINATION; WESTERN HEMISPHERE; COMPLICATION; IMMUNOLOGY;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HEPATITIS B VACCINES; HERPES ZOSTER VACCINE; HUMANS; INFLUENZA VACCINES; PAPILLOMAVIRUS VACCINES; PNEUMOCOCCAL VACCINES; VACCINATION;

EID: 85045614767     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. WOLFE F, MITCHELL DM, SIBLEY JT et al.: The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-94
2. GLUECK T, MUELLER-LADNER U: Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis 2008; 46: 1459-65
3. STRAND V, AHADIEH S, FRENCH J et al.: Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther 2015; 17: 362
4. DORAN MF, CROWSON CS, POND GR et al.: Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294-300
5. CROWSON CS, HOGANSON DD, FITZGIBBON PD, MATTESON EL: Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 2847-55
6. van ASSEN S, AGMON-LEVIN N, ELKAYAM O et al.: EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414-22
7. SINGH JA, SAAG KG, BRIDGES SL Jr et al.: 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016; 68: 1-26
8. FILLATREAU S: Regulatory roles of B cells in infectious diseases. Clin Exp Rheumatol 2016; 34 (Suppl. 98): S1-5
9. HMAMOUCHI I, WINTHROP K, LAUNAY O, DOUGADOS M: Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthitis: data from the international COMORA cohort. Vaccine 2015; 33: 1446-52
10. FEUCHTENBERGER M, KLEINERT S, SCHWAB S et al.: Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study. Rheumatol Int 2012; 32: 1533-9
11. CALABRO' A, CATERINO A, ELEFANTE E et al.: One year in review 2016: novelties in the treatment of rheumatoid arthritis Clin Exp Rheumatol 2016; 34: 357-72
12. SUBESINGHE S, RUTHERFORD AI, IBRAHIM F, HARRIS H, GALLOWAY J: A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK. BMC Musculoskelet Disord 2016; 17: 322
13. HUA C, MOREL J, ARDOUIN E et al.: Reasons for non-vaccination in French rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2015; 54: 748-50
14. COSTELLO R, WINTHROP KL, PYE SR, BROWN B, DIXON WG: Influenza and pneumococcal vaccination uptake in patients with rheumatoid arthritis treated with immunosuppressive therapy in the UK: A retrospective cohort study using data from the Clinical Practice Research Datalink. PLoS One 2016; 11: e0153848
15. LAMPROPOULOS C, ORFANOS P, BOURNIA V et al.: Adverce event and infections in patients with rheumatoid arthritis treated with conventional drug or biologic agents. A realworld study. Clin Exp Rheumatol 2015; 33: 216-24
16. FRIEDMAN MA, WINTHROP K: Vaccinations for rheumatoid arthritis. Curr Opin Rheumatol 2016; 28: 330-6
17. HAWKES D, BENHAMU J, SIDWELL T, MILES R, DUNLOP RA: Revisiting adverse reactions to vaccines: A critical appraisal of Autoimmune Syndrome Induced by Adjuvants (ASIA). J Autoimmun 2015; 59: 77-84
18. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2013-2014. 2013. Available at: http://www.cdc.gov/mmwr/ preview/mmwrhtml/rr6207a1.htm. Accessed May 2017
19. GROHSKOPF LA, SOKOLOW LZ, OLSEN SJ et al.: Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2015-16 influenza season. MMWR Morb Mortal Wkly Rep 2015; 64: 818-25
20. DIAZGRANADOS CA, DUNNING AJ, KIMMEL M et al.: Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014; 371: 635-45
21. IZURIETA HS, THADANI N, SHAY DK et al.: Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis 2015; 15: 293-300
22. van ASSEN S, HOLVAST A, BENNE CA et al.: Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62: 75-81
23. ELKAYAM O, BASHKIN A, MANDELBOIM M et al.: The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010; 39: 442-7
24. REHNBERG M, BRISSLERT M, AMU S et al.: Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther 2010; 12: R111
25. ARAD U, TZADOK S, AMIR S et al.: The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011; 29: 1643-8
26. RIBEIRO AC, GUEDES LK, MORAES JC et al.: Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis 2011; 70: 2144-7
27. IWAMOTO M, HOMMA S, ONISHI S et al.: Low level of seroconversion after a novel influenza A/H1N1/2009 vaccination in Japanese patients with rheumatoid arthritis in the 2009 season. Rheumatol Int 2012; 32: 3691-4
28. MORI S, UEKI Y, HIRAKATA N et al.: Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 2012; 71: 2006-10
29. WESTRA J, van ASSEN S, WILTING KR et al.: Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol 2014; 178: 40-7
30. KIVITZ AJ, SCHECHTMAN J, TEXTER M et al.: Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial. J Rheumatol 2014; 41: 648-57
31. WINTHROP KL, SILVERFIELD J, RACEWICZ A et al.: The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis 2016; 75: 687-95
32. ALTEN R, BINGHAM CO 3rd, COHEN SB et al.: Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. BMC Musculoskelet Disord 2016; 17: 231
33. AGMON-LEVIN N, KIVITY S, SHOENFELD Y: Influenza vaccine and autoimmunity. Isr Med Assoc J 2015; 11: 183-5
34. JIT M: The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis. J Infect 2010; 61; 114-24
35. O'BRIEN KL, WOLFSON LJ, WATT JP et al.: Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374: 893-902
36. SHEA KM, EDELSBERG J, WEYCKER D, FARKOUH RA, STRUTTON DR, PELTON SI: Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 2014; 1: ofu024
37. IZUMI Y, AKAZAWA M, AKEDA Y et al.: The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial. Arthritis Res Ther 2017; 19: 15
38. NAGEL J, GEBOREK P, SAXNE T et al.: The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients. Scand J Rheumatol 2015; 44: 271-9
39. MORI S, UEKI Y, AKEDA Y et al.: Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis 2013; 72: 1362-6
40. MIGITA K, AKEDA Y, AKAZAWA M et al.: Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. Arthritis Res Ther 2015; 17: 149
41. MIGITA K, AKEDA Y, AKAZAWA M et al.: Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients. Arthritis Res Ther 2015; 17: 357
42. MIGITA K, AKEDA Y, AKAZAWA M et al.: Opsonic and antibody responses to pneumococcal polysaccharide in rheumatoid arthritis patients receiving golimumab plus methotrexate. Medicine (Baltimore) 2015; 94: e2184
43. NAGEL J, GEBOREK P, SAXNE T et al.: The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients. Arthritis Res Ther 2015; 17: 124
44. RáKóCZI é, PERGE B, VéGH E et al.: Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept. Joint Bone Spine 2016; 83: 675-9
45. KAPETANOVIC MC, NAGEL J, NORDSTRöM I, SAXNE T, GEBOREK P, RUDIN A: Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine 2017; 35: 903-8
46. COOK IF, POND D, HARTEL G: Comparative reactogenicity and immunogenicity of 23-valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 2007; 25: 4767-74
47. BRYANT KA, BLOCK SL, BAKER SA et al.: Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 2010; 125: 866-75
48. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). 2012. Available at: https:// www.cdc.gov/mmwr/pdf/wk/mm6140.pdf. Accessed May 2017
49. INSINGA RP, ITZLER RF, PELLISSIER JM et al.: The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005; 20: 748-53
50. SMITTEN AL, CHOI HK, HOCHBERG MC et al.: The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007; 57: 1431e8
51. WINTHROP KL, YAMANAKA H, VALDEZ H et al.: Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 2014; 66: 2675e84
52. COHEN S, KOENING A, WANG L et al.: Efficacy and safety of Tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III. Clin Exp Rheumatol 2016; 34: 32-6
53. MORRISON VA, OXMAN MN, LEVIN MJ et al.: Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis 2013; 208: 559-63
54. YUN H, XIE F, BADDLEY JW, WINTHROP K, SAAG KG, CURTIS JR: Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases. J Rheumatol 2017. [Epub ahead of print]
55. HALES CM, HARPAZ R, ORTEGA-SANCHEZ I, BIALEK SR: Centers for Disease Control and Prevention CDC. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep 2014; 63: 729-31
56. HARPAZ R, ORTEGA-SANCHEZ IR, SEWARD JF: Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention CDC. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57: 1-30
57. RUBIN LG, LEVIN MJ, LJUNGMAN P et al.: 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58: 309-18
58. CUNNINGHAM AL, LAL H, KOVAC M et al.: Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016; 375: 1019-32
59. STRANGFELD A, LISTING J, HERZER P et al.: Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNFalpha agents. JAMA 2009; 301: 737e44
60. McDONALD JR, ZERINGUE AL, CAPLAN L et al.: Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48: 1364e71
61. GALLOWAY JB, MERCER LK, MOSELEY A et al.: Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013; 72: 229e34
62. ZHANG J, XIE F, DELZELL E et al.: Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308: 43-9
63. ZHANG J, DELZELL E, XIE F et al.: The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther 2011; 13: R174
64. KIM SC, GLYNN RJ, GIOVANNUCCI E et al.: Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis 2015; 74: 1360-7
65. PELLEGRINO P, RADICE S, CLEMENTI E: Immunogenicity and safety of the human papillomavirus vaccine in patients with autoimmune diseases: a systematic review. Vaccine 2015; 33: 3444-9
66. GöTESTAM SKORPEN C, HOELTZENBEIN M, TINCANI A et al.: The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75: 795-810
67. NARD FD, TODOERTI M, GROSSO V et al.: Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: extending perspective from old to newer drugs. World J Hepatol 2015; 7: 344-61
68. RYU HH, LEE EY, SHIN K et al.: Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFa agents: a retrospective analysis of 49 cases. Clin Rheumatol 2012; 31: 931-6
69. MORI S, FUJIYAMA S: Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations. World J Gastroenterol 2015; 21: 10274-89
70. PEREZ-ALVAREZ R, DIAZ-LAGARES C, GARCIA-HERNANDEZ F et al.: Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011; 90: 359-71
71. CARROLL MB, FORGIONE MA: Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 2010; 29: 1021-9
72. TAN J, ZHOU J, ZHAO P, WEI J: Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol 2012; 31: 1169-75
73. YEO W, CHAN TC, LEUNG NW et al.: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11
74. PEI SN, CHEN CH, LEE CM et al.: Reactivation of hepatitis B virus following rituximabbased regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010; 89: 255-62
75. SALINAS GF, de RYCKE L, BARENDREGT B et al.: Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis 2013; 72: 1037-43
76. GISBERT JP, VILLAGRASA JR, RODRIGUEZNOGUEIRAS A, CHAPARRO M: Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107: 1460-6
77. LOK AS, MCMAHON BJ: Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2
78. SORRELL MF, BELONGIA EA, COSTA J et al.: National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med 2009; 150: 104-10
79. WEINBAUM CM, WILLIAMS I, MAST EE et al.: Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57: 1-20